Nov. 14 at 9:18 PM
$MLTX I've been asked repeatedly if I like any other preclinical biopharma as much as MLTX. The answer is No.
However, if there is a second one I've talked to some Hedge Fund guys about this past month it's Structure Therapeutics.
$GPCR. (There's a few others, but I'll mention only my #2 here)
GPCR is also a small molecule type drug company with incredibly strong science &?leadership. The company appeals to scientific investors which is a guarantee they're doing things the right way.
Is GPCR a better choice than MLTX? NO.
Is GPCR going to succeed? YES.
$GPCR are a little behind
$MLTX & won't return the same profits as MLTX. But yes, they will be a player in the Ovesity/Endocrinology market & are headed in the same direction as Metsera with the Pfizer buyout.
If you consider which Hedge Funds back MLTX and GPCR... you'll discover a smart way to pick the right preclinical biopharma companies to invest your money. And it's not based on hype or Wall St analysts opinions.
